[PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].
Olsson
Anders G
AG
Institutionen för medicin och vård, Hälsouniversitetet, Universitetssjukhuset, Linköping. andol@imv.liu.se
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D011345:Fenofibrate / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D047495:PPAR gamma / Q000819:agonists*; D000077205:Pioglitazone; D016032:Randomized Controlled Trials as Topic; D045162:Thiazolidinediones / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D011345:Fenofibrate; D000077205:Pioglitazone